Serum Amphiregulin Differentiates Acute GI GVHD from Infectious Colitis | Synapse
March 3, 2026
Serum Amphiregulin Differentiates Acute GI GVHD from Infectious Colitis
Key Points
Acute gastrointestinal graft-versus-host disease can be differentiated effectively using serum amphiregulin levels, highlighting its potential as a biomarker.
Key evidence shows that higher amphiregulin levels correspond to cases of acute GI GVHD compared to infectious colitis, thus aiding diagnosis.
Observational analysis utilized serum amphiregulin measurements from patients to assess the presence of acute GI GVHD versus infectious colitis.
This finding supports the use of serum amphiregulin as a reliable diagnostic tool in managing acute GI GVHD, with implications for better clinical outcomes.